Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen
Lise Cuzin, Marine Morrier, Véronique Joly(Lyon 1 Université), Claudine Duvivier(Hôpital Necker-Enfants Malades), Clotilde Allavena(Centre Hospitalier Universitaire de Nantes), Jacques Reynes(Centre Hospitalier Universitaire de Montpellier), L. Khatchatourian(Inserm), Christine Jacomet, Giuseppe Vittorio De Socio(University of Perugia), André Cabie, Pierre Delobel, Corinne Isnard Bagnis, Philippe Flandre, David Rey(Hôpitaux Universitaires de Strasbourg), Firouzé Bani‐Sadr, Matthieu Hanf(Inserm), Tristan Ferry(Université Claude Bernard Lyon 1), Olivier Robineau(Inserm), Bruno Hoen(Inserm)
Université Pierre et Marie CURIE (UPMC)
December 1, 2017
Cited by 0
Related Papers
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344